Summary

for people ages 18-60 (full criteria)
at La Jolla, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this interventional study is to test and compare the effectiveness of two elimination diets—the 1-food elimination diet (1FED, milk only) and the 6-food elimination diet (6FED, milk, egg, wheat, soy, tree nut/peanuts, and fish/shellfish). The study will also test the effectiveness of swallowed glucocorticoid therapy in some of the study participants for whom diet therapy was not effective.

Official Title

Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial

Details

This study will consist of two phases, plus a screening period. During the screening period, subject eligibility for the study will be determined. During Phase 1, qualified participants will be randomly assigned to one of two elimination diet therapies--the 1FED or the 6FED. Participants will remain on the assigned dietary therapy for 6 weeks. At the end of 6 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status. Participants whose EoE is in remission (i.e. <15 eos/hpf) will be done with the study.

Participants whose EoE is still active (i.e. ≥15 eos/hpf) will continue into Phase 2 of the study. During Phase 2, participants who were on 1FED in Phase 1 will receive 6FED therapy for 6 weeks, and participants who were on 6FED during Phase 1 will receive swallowed glucocorticoid therapy for 6 weeks. At the end of 6 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status.

Keywords

Eosinophilic Gastrointestinal Disorders (EGIDs) Eosinophilic Esophagitis (EoE) Esophagitis Eosinophilic Esophagitis Digestive System Diseases Gastrointestinal Diseases Fluticasone Glucocorticoids elimination diet therapy Flovent

Eligibility

You can join if…

Open to people ages 18-60

  • Have diagnosis of EoE (based on consensus criteria)
  • Have histologically confirmed active disease >15 eosinophils/hpf in either distal or proximal esophagus within 4 weeks of screening visit
  • Symptomatic (have experienced symptoms within the last month prior to enrollment)
  • PPI confirmation
  • Have a negative urine pregnancy test at screening if of childbearing potential

You CAN'T join if...

  • Have been treated with topical swallowed steroids within the last 2 months or systemic steroids within the last 3 months
  • Have pathological eosinophilia in segments of the GI tract other than the esophagus determined by local review
  • Have been diagnosed with a GI malabsorption disorder (i.e., Inflammatory bowel disease, Crohn's disease) or Celiac disease
  • Are currently on dietary therapy strictly avoiding milk or on a 6FED
  • Have concurrent H pylori gastritis or parasitic infection
  • Have history of anaphylaxis to milk (with current avoidance of milk)
  • Have previously failed strict dietary therapy clearly documented with one of these regimens or topical steroid treatment (i.e. have achieved histological remission of<15 eos/hpf after having been on fluticasone or >1mg budesonide per day.
  • Use of investigational drugs within 4 weeks (one month) prior to enrollment
  • Are concurrently receiving any of the prohibited medications for the study
  • On immunotherapy for pollen (if not on maintenance therapy) or IgE-mediated food allergy
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Locations

  • University of California, San Diego accepting new patients
    La Jolla California 92093 United States
  • Northwestern University accepting new patients
    Chicago Illinois 60208 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Hospital Medical Center, Cincinnati
Links
https://www.rarediseasesnetwork.org/cms/CEGIR
ID
NCT02778867
Phase
Phase 2/3
Study Type
Interventional
Last Updated